Keyword Analysis & Research: senseonics


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
senseonics0.080.383221310

Keyword Research: People who searched senseonics also searched

Keyword CPC PCC Volume Score
senseonics1.680.5298586
senseonics stock1.760.8106818
senseonics holdings stock1.450.5203948
senseonics news1.41124044
senseonics eversense0.080.3714641
senseonics stocktwits1.640.1916754
senseonics holdings inc0.870.9279014
senseonics message board0.890.6403418
senseonics cgm1.440.4828268
senseonics incorporated1.940.1861235
senseonics stock price today0.750.5450882
senseonics yahoo finance1.850.171698
senseonics stock news0.590.94176100
senseonics eversense cgm0.220.9769430
senseonics investor relations0.190.7189841

Search Results related to senseonics on Search Engine

  • Senseonics

    senseonics.com

    https://www.senseonics.com/

    WEBSenseonics. News & Events. Publication. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Publication. Ascensia Diabetes Care launches patient assistance program to provide broader access to Eversense Continuous Glucose …

    DA: 3 PA: 73 MOZ Rank: 22

  • Senseonics Holdings, Inc. (SENS) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/SENS

    WEBFind the latest Senseonics Holdings, Inc. (SENS) stock quote, history, news and other vital information to help you with your stock trading and investing.

    DA: 61 PA: 37 MOZ Rank: 72

  • Senseonics Announces the Last Patient Completion of the 365 …

    senseonics.com

    https://www.senseonics.com/investor-relations/news-releases/2023/09-26-2023-130648721

    WEBSep 26, 2023 · Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study. September 26, 2023. Study Data to Support FDA Submission for the first 365-day Continuous Glucose Monitoring System. GERMANTOWN, Md. -- (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a …

    DA: 85 PA: 70 MOZ Rank: 98

  • Senseonics Holdings, Inc. Announces Business Updates

    senseonics.com

    https://www.senseonics.com/investor-relations/news-releases/2024/01-02-2024-210523872

    WEBSenseonics Holdings, Inc. Announces Business Updates. January 02, 2024. GERMANTOWN, Md. -- (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with …

    DA: 98 PA: 70 MOZ Rank: 45

  • Investor Relations – Senseonics

    senseonics.com

    https://www.senseonics.com/investor-relations

    WEBMar 8, 2024 · Investor Relations. We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring, or CGM, system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.

    DA: 25 PA: 6 MOZ Rank: 76

  • FDA approves first continuous glucose monitoring system with a …

    fda.gov

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-continuous-glucose-monitoring-system-fully-implantable-glucose-sensor-and

    WEBFDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes. The U.S. Food and Drug Administration today ...

    DA: 53 PA: 44 MOZ Rank: 95

  • Senseonics Announces FDA Approval of the Eversense® E3 …

    senseonics.com

    https://www.senseonics.com/investor-relations/news-releases/2022/02-11-2022-120033959

    WEBSenseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook. February 11, 2022. The world’s first and only long-term implantable CGM system now offers patients exceptional accuracy for 6 months. GERMANTOWN, Md. -- (BUSINESS WIRE)-- …

    DA: 67 PA: 1 MOZ Rank: 66

  • Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial …

    senseonics.com

    https://www.senseonics.com/investor-relations/news-releases/2022/11-08-2022-210538515

    WEBNov 8, 2022 · Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.

    DA: 38 PA: 34 MOZ Rank: 38

  • News Releases 2022 – Senseonics

    senseonics.com

    https://www.senseonics.com/investor-relations/news-releases/2022

    WEBNov 9, 2022 · Download. Senseonics to Present at the Stifel 2022 Healthcare Conference 11/09/2022. Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results 11/08/2022. Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At …

    DA: 86 PA: 71 MOZ Rank: 30

  • Senseonics seeks iCGM designation for implantable glucose …

    medtechdive.com

    https://www.medtechdive.com/news/senseonics-icgm-designation-365-day-sensor-fda/690663/

    WEBAug 11, 2023 · Senseonics expects approval for the iCGM designation in early 2024, Goodnow told investors. The CEO did not disclose which pump companies Senseonics will partner with, noting that the company “has a number of development programs currently in place,” and that insulin pens are also an important consideration, given that more people …

    DA: 67 PA: 90 MOZ Rank: 91